Europe Lipids Market, By Type (Natural Lipids and Synthetic Lipids), Lipid System (Neutral Lipids, Bacterial Lipids, Fluorescent Lipids, Bioactive Lipids, Polymerizable Lipids, Headgroup Modified Lipids, and Others), Delivery System (Liposomes, Solid Lipid Nanoparticles, Nanostructures Lipid Carrier, Niosomes, Transferosomes, and Others), Source (Egg Yolk, Soyabean, Non-GMO Soyabean, Purified Oils, Purified Fatty Acids, and Others), End User (Pharmaceutical Industries, Biotechnology Industries, Academic and Research Institutes, Cosmetic Industries and Others), Distribution Channel (Direct Tender, Retail Sales and Others) - Industry Trends and Forecast to 2030.
Europe Lipids Market Analysis and Insights
The growing prevalence of chronic diseases globally has enhanced the demand of the market. The rising healthcare expenditure for better health services are also attributing in the growth of the market. The major market players are highly focusing on various product launches and drug approvals during this crucial period. In addition, the increasing demand for lipids in various other industries such as food and beverage, cosmetic industries and among others also contributing in the rising demand for lipids market.
The increasing healthcare expenditure, strategic initiatives by market players and are giving opportunities to the market. However, different manufacturing challenges for lipid nanoparticles production and lack of healthcare facilities in emerging economies are key challenges for the market growth.
Europe lipids market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.9% in the forecast period of 2023 to 2030 and is expected to reach USD 6,708.58 million by 2030 from USD 3,392.06 million in 2022.
Report Metric
|
Details
|
Forecast Period
|
2023 to 2030
|
Base Year
|
2022
|
Historic Years
|
2021 (Customisable to 2020-2015)
|
Quantitative Units
|
Revenue in USD Million
|
Segments Covered
|
By Type (Natural Lipids and Synthetic Lipids), Lipid System (Neutral Lipids, Bacterial Lipids, Fluorescent Lipids, Bioactive Lipids, Polymerizable Lipids, Headgroup Modified Lipids, and Others), Delivery System (Liposomes, Solid Lipid Nanoparticles, Nanostructures Lipid Carrier, Niosomes, Transferosomes, and Others), Source (Egg Yolk, Soyabean, Non-GMO Soyabean, Purified Oils, Purified Fatty Acids, and Others), End User (Pharmaceutical Industries, Biotechnology Industries, Academic and Research Institutes, Cosmetic Industries and Others), Distribution Channel (Direct Tender, Retail Sales and Others)
|
Countries Covered
|
Germany, France, U.K., Italy, Spain, Netherlands, Russia, Belgium, Switzerland, Turkey and Rest of Europe.
|
Market Players Covered
|
Alnylam Pharmaceutical, Inc., Croda International Plc., Moderna Inc., BioNTech SE., Pfizer Inc., Evonik Industries AG, Lipoid GmbH, Matreya LLC, VAV Life Sciences Pvt Ltd., Curia Europe Inc., Cargill, Incorporated, Gattefossé, CD Bioparticles, Merck KGaA, NOF EUROPE GmbH, ABITEC, Cayman Chemical, CordenPharma International, CHEMI S.p.A., DSM, BASF SE, Tokyo Chemical Industry Co., Ltd., ADMSIO, Stepan Company, and Kerry
|
Market Definition
Lipids can be defined as a group of organic compounds found in animals, plants, and micro- organisms. They include sterols, waxes, fats, and fat soluble vitamins. Lipids hold an ability to execute various activities. At the same time, they are known for having low toxicity levels. These qualities of lipids help in effective drug delivery. As a result, they are increasingly used as excipients in the drug production. This factor is fueling the growth of the Europe pharmaceutical lipids market.
In recent period, the worldwide healthcare sector is going through remarkable changes. Development in drug delivery technology along with the incorporation of drug formularies is working as a driver for the growth of the pharmaceutical lipids market. Growth in quick chronic health issues and quick resulting drug delivery to the patient is one of the key factors pushing the growth of the Europe pharmaceutical lipids market.
Lipids Market Dynamics
Drivers
-
Increase in the prevalence of chronic diseases
The encumbrance of chronic disease is briskly increasing across the globe. According to the WHO (World Health Organization), in 2021, the contribution of chronic disease was about 60%, which accounted for the number of deaths. In most Western countries, the major reason behind the increasing number of chronic diseases is the continuous increase in the aged population. The rise in the number of chronic diseases such as cardiovascular diseases, neurological disorders, and various other chronic diseases has led to an increase in the demand for various medicinal drugs that will drive the growth of the Europe lipids market in the coming years.
-
Rising demand for lipids in food and beverage as well as the cosmetic industry
The demand for lipids in pharmaceuticals is very high as it is used in developing various drugs in the market. Also, the demand for lipids has increased in various other industries, such as in food & beverage and cosmetic products.
Lipids are an essential ingredient in the formulation of dietary supplements owing to their high content of energy and fat-soluble vitamins. Increasing health concern among people in light of COVID-19 has propelled the Europe demand for dietary supplements. Furthermore, the availability of dietary supplements in multiple forms and flavours has made them more socially acceptable to all age groups. Growing dietary supplement consumption is expected to boost the demand for lipids over the projected years.
-
Rise in drug development
In the pharmaceutical industry, lipids and polymers are considered pillar excipients for formulating various drugs. They are used as stabilizers, solubilizes, permeation enhancers, and transfection agents. Increasing adoption of a wide range of natural, synthetic, semi-synthetic or completely artificial lipids and polymers in the formulation of various dosage forms is expected to boost the market over the forecast period.
Opportunities
-
Rise in healthcare expenditure
Healthcare expenditure has increased worldwide as people's disposable income in various countries increases. Moreover, to accomplish the population requirements, government bodies and healthcare organizations are taking the initiative to accelerate healthcare expenditure. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities for various diseases is highly prevalent in recent years.
-
Strategic initiatives by major players
Increasing rates of various types of disease and their severity are widely seen among people globally. The dramatic rise in research quality and increasing research opportunities is because of various strategic initiatives the market players take. They are taking initiatives such as product launch, collaborations, mergers, acquisitions, and many more over the years and is expected to lead and create more opportunities in the market. Evonik invested in the short-term growth of its specialty lipids production at its Hanau and Dossenheim locations in Germany, which supplied two of the four lipids for the Pfizer/BioNTech vaccine. According to Spencer, the first batches were delivered to BioNTech in April 2021, months ahead of schedule.
Restraints/Challenges
- High cost of lipid synthesis and increasing cost of raw materials
Lipid based drugs require a huge cost for the development process. As the concept needs to be locked down, the materials need to be sourced, and it is important to consider lead times. Additionally, the process is time consuming as the drug needs sufficient time to fulfil all the clinical trials before bringing in the market for use.
Furthermore, any changes that must be re-verified will impact time. The growing advancements in biosensor assay formats and other complementary technologies demanded an effective investment for successful operations and a project risk management plan. The establishment of R&D for conducting research entails high costs, leading to expensive drugs. Thus, this factor is a major restraint for the Europe lipids market.
- Different manufacturing challenges for lipid nanoparticle production
Lipid nanoparticles have made a major impact on the pharmaceutical industry. At their core, lipid nanoparticles (LNPs) are delivery carriers that safeguard nucleic acids. As an integral part of recent mRNA vaccines, they are injected and transported to the intended site in the cell. Despite the many advantages of lipid nanoparticles as delivery systems, the pharmaceutical industry must address significant manufacturing challenges.
These challenges include:
- Precisely controlled particle size/size distributions
- Sterilization issues
- Process repeatability and scalability
- Regulatory requirements (such as cGMP regulations)
Post COVID-19 Impact on Lipids Market
The COVID-19 has positively affected the market. As the demand for COVID-19 vaccine was on the great demand and the positive point here is the lipid is majorly used in the vaccine production. Thus COVID-19 affected lipids market positively.
Recent Developments
- In November 2022, BioNTech SE announced its Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities. The acquisition is part of BioNTech’s expansion strategy to strengthen its Europe footprint in Asia.
- In September 2021, U.S. ingredients supplier ABITEC Corporation signed an amended agreement with DKSH to distribute its specialty lipids into new markets and regions across Europe. This has helped the company to expand its business in various regions.
Europe Lipids Market Scope
Europe lipids market is segmented into, type, lipid systems, delivery systems, source, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Natural Lipid
- Synthetic Lipids
On the basis of type, the Europe lipids market is segmented into natural lipid and synthetic lipid.
Lipid Systems
- Bioactive Lipids
- Polymerizable Lipids
- Fluorescent Lipids
- Bacterial Lipids
- Neutral Lipids
- Headgroup Modified Lipids
- Others
Based on lipid systems, the Europe lipids market is segmented into neutral lipids, bacterial lipids, fluorescent lipids, bioactive lipids, polymerizable lipids, headgroup modified lipids and others.
Delivery Systems
- Liposomes
- Solid Lipid Nanoparticles
- Nanostructures Lipid Carrier
- Transferosomes
- Niosomes
- Others
Based on delivery systems, the Europe lipids market is segmented into liposomes, solid lipid nanoparticles, nanostructures lipid carrier, niosomes, transferosomes and others.
Source
- Purified Fatty Acids
- Purified Oils
- Egg Yolk
- Soyabean
- Non-GMO Soyabean
- Others
Based on source, the Europe lipids market is segmented into egg yolk, soyabean, non-GMO soyabean, purified oils, purified fatty acids and others.
End User
- Pharmaceutical Industries
- Biotechnology Industries
- Cosmetic Industry
- Academic and Research Institutes
- Others
Based on end user, the Europe lipids market is segmented into pharmaceutical industries, biotechnology industries, academic and research institutes, cosmetic industries and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
Based on distribution channel, the Europe lipids market is segmented into direct tender, retail sales and others.
Lipids market Regional Analysis/Insights
The lipids market is analysed and market size insights and trends are provided by country, type, lipid systems, delivery systems, source, end user and distribution channel.
Countries covered in lipids market are Germany, France, U.K., Italy, Spain, Netherlands, Russia, Belgium, Switzerland, Turkey, and Rest of Europe. Germany dominates the lipids marketing terms of market share and market revenue and will continue to flourish its dominance during the forecast period.
Germany is expected to grow due to rise in chronic diseases owing to high demand for pharmaceutical drugs and rising demand for lipids in different industries are expected to drive the regional market in the forecasted period.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Lipids Market Share Analysis
The lipids market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on lipids market.
Some of the major players operating in the lipids market Alnylam Pharmaceutical, Inc., Croda International Plc., Moderna Inc., BioNTech SE., Pfizer Inc., Evonik Industries AG, Lipoid GmbH, Matreya LLC, VAV Life Sciences Pvt Ltd., Curia Europe Inc., Cargill, Incorporated, Gattefossé, CD Bioparticles, Merck KGaA, NOF EUROPE GmbH, ABITEC, Cayman Chemical, CordenPharma International, CHEMI S.p.A., DSM, BASF SE, Tokyo Chemical Industry Co., Ltd., ADMSIO, Stepan Company, and Kerry among others.
SKU-